In the past few years, targeted therapies, such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitors, have achieved great success in the treatment of NSCLC. Here, ALK is linked to non-small cell lung carcinoma.